DoD, HHS Sign $375M Procurement Deal for Eli Lilly COVID-19 Drug

DoD, HHS Sign $375M Procurement Deal for Eli Lilly COVID-19 Drug
Eli Lilly

Eli Lilly and Co. (NYSE: LLY) has received a potential $375M contract from the departments of Defense and Health and Human Services to initially supply 300K doses of bamlanivimab, an investigational monoclonal antibody drug for COVID-19.

The agreement includes an option for the federal government to buy through the end of June 2021 up to 650K more doses of the experimental LY-CoV555 treatment worth approximately $812.5M, DoD said Wednesday.

“This agreement with Eli Lilly is part of Operation Warp Speed’s efforts to position the federal government to distribute potential therapeutics, allowing faster distribution if trials are successful,” said HHS Secretary Alex Azar.

Eli Lilly is conducting Phase 3 trials of bamlanivimab in addition to clinical studies being carried out as part of the Accelerating COVID-19 Therapeutic Interventions and Vaccines partnership announced in April.

The Food and Drug Administration is evaluating LY-CoV555 for use in outpatient care and the federal government will distribute the drug once it receives FDA approval. Bamlanivimab is designed to weaken the ability of the virus to infect cells in the human body by binding to the virus’ certain proteins.

You may also be interested in...

Dedrone

Ben Wenger Named Dedrone Chief Revenue Officer, Mary-Lou Smulders Appointed Chief Marketing Officer

Dedrone has named Ben Wenger, a two-decade enterprise technology sales veteran, as chief revenue officer and appointed Mary-Lou Smulders, strategic adviser at the counter-drone platform maker since February 2020, as chief marketing officer.

D.J. Dart VP

SAIC Promotes DJ Dart as DHS Enterprise VP

D.J. Dart, formerly business development executive for the Department of Homeland Security at Science Applications International Corp. (NYSE: SAIC), has elevated to the role of vice president for DHS enterprise. He joined SAIC through its acquisition of the Unisys Federal business in March 2020.